Logo image of CAI

CARIS LIFE SCIENCES INC (CAI) Stock Fundamental Analysis

USA - NASDAQ:CAI - US1421521071 - Common Stock

31.8 USD
+0.02 (+0.06%)
Last: 10/6/2025, 10:03:40 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CAI. CAI was compared to 536 industry peers in the Biotechnology industry. While CAI seems to be doing ok healthwise, there are quite some concerns on its profitability. CAI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CAI has reported negative net income.
The reported net income has been mixed in the past 5 years: CAI reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CAI reported negative operating cash flow in multiple years.
CAI Yearly Net Income VS EBIT VS OCF VS FCFCAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

CAI has a Return On Assets of -39.61%. This is comparable to the rest of the industry: CAI outperforms 59.89% of its industry peers.
CAI has a Return On Equity (-83.52%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -39.61%
ROE -83.52%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CAI Yearly ROA, ROE, ROICCAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

With a decent Gross Margin value of 43.77%, CAI is doing good in the industry, outperforming 74.81% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAI Yearly Profit, Operating, Gross MarginsCAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

CAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAI remains at a similar level compared to 1 year ago.
Compared to 5 years ago, CAI has more shares outstanding
CAI has a worse debt/assets ratio than last year.
CAI Yearly Shares OutstandingCAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2023 2024 50M 100M 150M 200M 250M
CAI Yearly Total Debt VS Total AssetsCAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2023 2024 1B 2B 3B

2.2 Solvency

CAI has an Altman-Z score of 7.26. This indicates that CAI is financially healthy and has little risk of bankruptcy at the moment.
CAI has a Altman-Z score of 7.26. This is in the better half of the industry: CAI outperforms 79.48% of its industry peers.
A Debt/Equity ratio of 0.82 indicates that CAI is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.82, CAI is not doing good in the industry: 74.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Altman-Z 7.26
ROIC/WACCN/A
WACC9.82%
CAI Yearly LT Debt VS Equity VS FCFCAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

CAI has a Current Ratio of 9.24. This indicates that CAI is financially healthy and has no problem in meeting its short term obligations.
CAI has a better Current ratio (9.24) than 78.92% of its industry peers.
CAI has a Quick Ratio of 8.79. This indicates that CAI is financially healthy and has no problem in meeting its short term obligations.
CAI's Quick ratio of 8.79 is fine compared to the rest of the industry. CAI outperforms 76.87% of its industry peers.
Industry RankSector Rank
Current Ratio 9.24
Quick Ratio 8.79
CAI Yearly Current Assets VS Current LiabilitesCAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

CAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.22%, which is quite good.
The Revenue has grown by 34.67% in the past year. This is a very strong growth!
Measured over the past years, CAI shows a small growth in Revenue. The Revenue has been growing by 6.64% on average per year.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A

3.2 Future

CAI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -28.69% yearly.
Based on estimates for the next years, CAI will show a very strong growth in Revenue. The Revenue will grow by 36.53% on average per year.
EPS Next Y-137.14%
EPS Next 2Y-80.18%
EPS Next 3Y-46.01%
EPS Next 5Y-28.69%
Revenue Next Year63.34%
Revenue Next 2Y54.33%
Revenue Next 3Y43.5%
Revenue Next 5Y36.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CAI Yearly Revenue VS EstimatesCAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B
CAI Yearly EPS VS EstimatesCAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CAI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 115.54 indicates a quite expensive valuation of CAI.
CAI's Price/Forward Earnings ratio is rather cheap when compared to the industry. CAI is cheaper than 86.94% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of CAI to the average of the S&P500 Index (23.32), we can say CAI is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 115.54
CAI Price Earnings VS Forward Price EarningsCAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAI Per share dataCAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

CAI's earnings are expected to decrease with -46.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-80.18%
EPS Next 3Y-46.01%

More info and screens

0

5. Dividend

5.1 Amount

CAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARIS LIFE SCIENCES INC

NASDAQ:CAI (10/6/2025, 10:03:40 AM)

31.8

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners35.5%
Inst Owner Change0%
Ins Owners48.84%
Ins Owner Change9.39%
Market Cap8.94B
Analysts86.67
Price Target39.91 (25.5%)
Short Float %1.66%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.77%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-70.87%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)3.1%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 115.54
P/S 21.69
P/FCF N/A
P/OCF N/A
P/B 19.75
P/tB 20.63
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)0.28
Fwd EY0.87%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.47
BVpS1.61
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.61%
ROE -83.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.77%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.24
Quick Ratio 8.79
Altman-Z 7.26
F-ScoreN/A
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-137.14%
EPS Next 2Y-80.18%
EPS Next 3Y-46.01%
EPS Next 5Y-28.69%
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
Revenue Next Year63.34%
Revenue Next 2Y54.33%
Revenue Next 3Y43.5%
Revenue Next 5Y36.53%
EBIT growth 1Y19.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.94%
EBIT Next 3Y48.79%
EBIT Next 5Y34.98%
FCF growth 1Y15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.19%
OCF growth 3YN/A
OCF growth 5YN/A